<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432237</url>
  </required_header>
  <id_info>
    <org_study_id>0974-016</org_study_id>
    <secondary_id>2006_526</secondary_id>
    <nct_id>NCT00432237</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 in the Acute Treatment of Migraine With or Without Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a
      placebo for acute migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Reporting Pain Freedom at 2 Hours Postdose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Pain Freedom was defined as a reduction of a Grade 2 or 3 severity migraine at baseline to a no pain (Grade 0) at 2 hours post dose.
Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Pain Relief at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours post dose.
Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Absence of Photophobia at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Respective experience (yes/no) of migraine-associated symptoms (including photophobia) was recorded by the patient in a diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Absence of Phonophobia at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Respective experience (yes/no) of migraine-associated symptoms (including phonophobia) was recorded by the patient in a diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Absence of Nausea at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Respective experience (yes/no) of migraine-associated symptoms (including nausea) was recorded by the patient in a diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Have Sustained Pain-Freedom From 2 to 24 Hours Postdose</measure>
    <time_frame>2 to 24 hours postdose</time_frame>
    <description>Pain Freedom at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 24 hours after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Have Total Migraine Freedom 2 to 24 Hours Postdose</measure>
    <time_frame>2 to 24 hours postdose</time_frame>
    <description>Pain Freedom and no migraine-associated symptoms at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache or migraine-associated symptom during the 24 hours after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Have Total Migraine Freedom 2 Hours Postdose</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Pain Freedom and no migraine-associated symptoms at 2 hours postdose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1703</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>MK0974 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK0974 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK0974 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0974 50 mg</intervention_name>
    <arm_group_label>MK0974 50 mg</arm_group_label>
    <other_name>MK0974</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0974 150 mg</intervention_name>
    <arm_group_label>MK0974 150 mg</arm_group_label>
    <other_name>MK0974</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0974 300 mg</intervention_name>
    <arm_group_label>MK0974 300 mg</arm_group_label>
    <other_name>MK0974</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has at least 1 year history of migraine (with or without aura)

          -  Females of childbearing years must use acceptable contraception throughout trial

        Exclusion Criteria:

          -  Patient is pregnant/breast-feeding (or is a female expecting to conceive during the
             study period)

          -  Patient has history or evidence of uncontrolled diabetes, or Human Immunodeficiency
             Virus (HIV) disease. Patient has uncontrolled cardiovascular disease

          -  Patient has major depression, other pain syndromes that might interfere with study
             assessments, psychiatric conditions, dementia, or significant neurological disorders
             (other than migraine)

          -  Patient has a history of gastric or small intestinal surgery or has a disease that
             causes malabsorption

          -  Patient has a history of cancer within the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009 Sep 22;73(12):970-7. doi: 10.1212/WNL.0b013e3181b87942.</citation>
    <PMID>19770473</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2007</study_first_submitted>
  <study_first_submitted_qc>February 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2007</study_first_posted>
  <results_first_submitted>July 19, 2010</results_first_submitted>
  <results_first_submitted_qc>November 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2010</results_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 83 centers worldwide that participated: United States (36), Latin America (9), and Europe (38). First Patient Treated = 25 March 2007, and Last Patient Last Treatment = 29 November 2007.</recruitment_details>
      <pre_assignment_details>Participants were assessed, using the protocol inclusion and exclusion criteria, at Visit 1, and if eligible were randomized at that same visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK0974 50 mg</title>
          <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
        </group>
        <group group_id="P2">
          <title>MK0974 150 mg</title>
          <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
        </group>
        <group group_id="P3">
          <title>MK0974 300 mg</title>
          <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244">1 patient in the MK0974 50 mg group was treated but withdrew consent.</participants>
                <participants group_id="P2" count="485"/>
                <participants group_id="P3" count="484">1 patient in the MK0974 300 mg group was treated but withdrew consent.</participants>
                <participants group_id="P4" count="490"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed--With Data</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="381"/>
                <participants group_id="P3" count="370"/>
                <participants group_id="P4" count="365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed--No Data</title>
              <participants_list>
                <participants group_id="P1" count="1">For patients in this category, diaries were collected but lost prior to data entry.</participants>
                <participants group_id="P2" count="3">For patients in this category, diaries were collected but lost prior to data entry.</participants>
                <participants group_id="P3" count="5">For patients in this category, diaries were collected but lost prior to data entry.</participants>
                <participants group_id="P4" count="1">For patients in this category, diaries were collected but lost prior to data entry.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="384"/>
                <participants group_id="P3" count="375"/>
                <participants group_id="P4" count="366"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Qualifying Event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK0974 50 mg</title>
          <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
The reported number of participants are all patients randomized who received study drug and completed the study.</description>
        </group>
        <group group_id="B2">
          <title>MK0974 150 mg</title>
          <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
The reported number of participants are all patients randomized who received study drug and completed the study.</description>
        </group>
        <group group_id="B3">
          <title>MK0974 300 mg</title>
          <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
The reported number of participants are all patients randomized who received study drug and completed the study.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
The reported number of participants are all patients randomized who received study drug and completed the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="381"/>
            <count group_id="B3" value="371"/>
            <count group_id="B4" value="365"/>
            <count group_id="B5" value="1294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline Characteristics are for the subset of randomized patients who were treated</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="11.3"/>
                    <measurement group_id="B2" value="41.6" spread="11.0"/>
                    <measurement group_id="B3" value="41.8" spread="11.6"/>
                    <measurement group_id="B4" value="41.9" spread="11.9"/>
                    <measurement group_id="B5" value="41.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline Characteristics are for the subset of randomized patients who were treated</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="320"/>
                    <measurement group_id="B4" value="318"/>
                    <measurement group_id="B5" value="1123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Baseline Characteristics are for the subset of randomized patients who were treated</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="302"/>
                    <measurement group_id="B4" value="303"/>
                    <measurement group_id="B5" value="1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Severity</title>
          <description>Baseline severity was self-reported by the patient and recorded in the take-home diary. Patients were instructed not to dose until they had experienced either a moderate or severe migraine, with migraine pain rated on a 4-point scale (No Pain=0, Mild Pain=1, Moderate Pain=2, Severe Pain=3). Baseline Characteristics are for the subset of randomized patients who were treated.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="237"/>
                    <measurement group_id="B4" value="235"/>
                    <measurement group_id="B5" value="834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Severity missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Pain Freedom at 2 Hours Postdose</title>
        <description>Pain Freedom was defined as a reduction of a Grade 2 or 3 severity migraine at baseline to a no pain (Grade 0) at 2 hours post dose.
Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Pain Freedom at 2 Hours Postdose</title>
          <description>Pain Freedom was defined as a reduction of a Grade 2 or 3 severity migraine at baseline to a no pain (Grade 0) at 2 hours post dose.
Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="369"/>
                <count group_id="O4" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Have Sustained Pain-Freedom From 2 to 24 Hours Postdose</title>
        <description>Pain Freedom at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 24 hours after dosing with study medication.</description>
        <time_frame>2 to 24 hours postdose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours and who either 1) did not have pain freedom at any time between 2 and 24 hours postdose, 2) used rescue medication between 2 and 24 hours postdose or 3) answered the 24 hour recurrence question (a question that ascertains recurrence of migraine pain)</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Have Sustained Pain-Freedom From 2 to 24 Hours Postdose</title>
          <description>Pain Freedom at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 24 hours after dosing with study medication.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours and who either 1) did not have pain freedom at any time between 2 and 24 hours postdose, 2) used rescue medication between 2 and 24 hours postdose or 3) answered the 24 hour recurrence question (a question that ascertains recurrence of migraine pain)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Pain Relief at 2 Hours Post Dose</title>
        <description>Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours post dose.
Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Pain Relief at 2 Hours Post Dose</title>
          <description>Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours post dose.
Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="369"/>
                <count group_id="O4" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="205"/>
                    <measurement group_id="O4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Absence of Photophobia at 2 Hours Post Dose</title>
        <description>Respective experience (yes/no) of migraine-associated symptoms (including photophobia) was recorded by the patient in a diary.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Absence of Photophobia at 2 Hours Post Dose</title>
          <description>Respective experience (yes/no) of migraine-associated symptoms (including photophobia) was recorded by the patient in a diary.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="369"/>
                <count group_id="O4" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="179"/>
                    <measurement group_id="O4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Absence of Phonophobia at 2 Hours Post Dose</title>
        <description>Respective experience (yes/no) of migraine-associated symptoms (including phonophobia) was recorded by the patient in a diary.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Absence of Phonophobia at 2 Hours Post Dose</title>
          <description>Respective experience (yes/no) of migraine-associated symptoms (including phonophobia) was recorded by the patient in a diary.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="369"/>
                <count group_id="O4" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="206"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Absence of Nausea at 2 Hours Post Dose</title>
        <description>Respective experience (yes/no) of migraine-associated symptoms (including nausea) was recorded by the patient in a diary.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Absence of Nausea at 2 Hours Post Dose</title>
          <description>Respective experience (yes/no) of migraine-associated symptoms (including nausea) was recorded by the patient in a diary.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="369"/>
                <count group_id="O4" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="260"/>
                    <measurement group_id="O3" value="258"/>
                    <measurement group_id="O4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Have Total Migraine Freedom 2 to 24 Hours Postdose</title>
        <description>Pain Freedom and no migraine-associated symptoms at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache or migraine-associated symptom during the 24 hours after dosing with study medication.</description>
        <time_frame>2 to 24 hours postdose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours and who either 1) did not have pain freedom at any time between 2 and 24 hours postdose, 2) used rescue medication between 2 and 24 hours postdose or 3) answered the 24 hour recurrence question (a question that ascertains recurrence of migraine pain)</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Have Total Migraine Freedom 2 to 24 Hours Postdose</title>
          <description>Pain Freedom and no migraine-associated symptoms at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache or migraine-associated symptom during the 24 hours after dosing with study medication.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours and who either 1) did not have pain freedom at any time between 2 and 24 hours postdose, 2) used rescue medication between 2 and 24 hours postdose or 3) answered the 24 hour recurrence question (a question that ascertains recurrence of migraine pain)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Have Total Migraine Freedom 2 Hours Postdose</title>
        <description>Pain Freedom and no migraine-associated symptoms at 2 hours postdose.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0974 50 mg</title>
            <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O2">
            <title>MK0974 150 mg</title>
            <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O3">
            <title>MK0974 300 mg</title>
            <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Have Total Migraine Freedom 2 Hours Postdose</title>
          <description>Pain Freedom and no migraine-associated symptoms at 2 hours postdose.</description>
          <population>All randomized, treated patients who have at least one post-dose measurement at or prior to 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="380"/>
                <count group_id="O3" value="369"/>
                <count group_id="O4" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P-value constructed using a logistic model adjusting for baseline severity (moderate, severe), region (US, ex-US), treatment and age (continuous).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from the time that the patient was first treated with study therapy through 14 days following the last dose of study therapy.</time_frame>
      <desc>Subjective adverse experiences were recorded by the patient in a paper diary.
Patients were counted in the treatment group for which they actually took study drug. One patient gave some of their study drug to another patient; resulting in the difference in 2 groups of 1 from what was reported in the Participant Flow &quot;Completed--With Data&quot;.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK0974 50 mg</title>
          <description>MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack</description>
        </group>
        <group group_id="E2">
          <title>MK0974 150 mg</title>
          <description>MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack</description>
        </group>
        <group group_id="E3">
          <title>MK0974 300 mg</title>
          <description>MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="370"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

